Cryptococcus neoformans in organ transplant recipients: Impact of calcineurin-inhibitor agents on mortality

Journal of Infectious Diseases

Volumn 195, Issue 5, 2007, Pages 756-764

  Singh, Nina ^a,w   Alexander, Barbara D ^b   Lortholary, Olivier ^q   Dromer, Françoise ^q   Gupta, Krishan L ^r   John, George T ^s   Del Busto, Ramon ^c   Klintmalm, Goran B ^d   Somani, Jyoti ^e   Lyon, G Marshall ^e   Pursell, Kenneth ^f   Stosor, Valentina ^g   Muňoz, Patricia ^t   Limaye, Ajit P ^h   Kalil, Andre C ⁱ   Pruett, Timothy L ^j   Garcia Diaz, Julia ^l   Humar, Atul ^u   Houston, Sally ^m   House, Andrew A ^v   Wray, Dannah ^o   Orloff, Susan ^p   Dowdy, Lorraine A ⁿ   Fisher, Robert A ^k   Heitman, Joseph ^b   Wagener, Marilyn M ^a   Husain, Shahid ^a   Antoine, Corinne ^x   Benoît, Barrou ^y   Heng, Anne Elisabeth ^z   Legendre, Christophe ^aa   Michelet, Christian ^ab   Ponceau, Bénédicte ^ac   Ouali, Nacéra ^ad   Stern, Marc ^ae   Sheppard, Theresa ^c   Lyon, Marshall ^e   more..

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c HENRY FORD HOSPITAL   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e EMORY UNIVERSITY   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^j UNIVERSITY OF VIRGINIA   (United States)

^k VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^l OCHSNER CLINIC FOUNDATION   (United States)

^m UNIVERSITY OF SOUTH FLORIDA   (United States)

ⁿ UNIVERSITY OF MIAMI   (United States)

^o MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^p OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^q INSTITUT PASTEUR   (France)

^r POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^s CHRISTIAN MEDICAL COLLEGE   (India)

^t HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^u TORONTO GENERAL HOSPITAL   (Canada)

^v UNIVERSITY OF WESTERN ONTARIO   (Canada)

^w VETERANS AFFAIRS MEDICAL CENTER   (United States)

^x SAINT LOUIS HOSPITAL   (France)

^y PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^z SERVICE DE RHUMATOLOGIE   (France)

^aa HÔPITAL NECKER ENFANTS MALADES   (France)

^ab PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^ac CROIX ROUSSE HOSPITAL   (France)

^ad HÔPITAL TENON   (France)

^ae FOCH HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; FLUCONAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DISEASE SEVERITY; FEMALE; FUNGEMIA; GRAFT REJECTION; HIGH RISK POPULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MORTALITY; MULTIVARIATE ANALYSIS; NONHUMAN; ORGAN TRANSPLANTATION; PATHOGENESIS; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; CALCINEURIN; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; TREATMENT OUTCOME;

EID: 33847064677     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/511438     Document Type: Article

References (49)

1. Kanj SS, Welty-Wolf K, Madden J, et al. Fungal infections in lung and heart-lung transplant recipients: report of 9 cases and review of the literature. Medicine 1996; 75:142-56.
2. Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993; 16:677-88.
3. Fortun J, Martin-Davila P, Moreno S, et al. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother 2003; 52:813-9.
4. Singh N, Wagener MM, Marino IR, Gayowski T. Trends in invasive fungal infections in liver transplant recipients: correlation with evolution in transplantation practices. Transplantation 2002; 73:63-7.
5. Husain C, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis 2001; 7:375-81.
6. John GT, Mathew M, Snehaltha E, et al. Cryptococcosis in renal allograft recipients. Transplantation 1994; 58:855-6.
7. Goldman DL, Rhine H, Abadi J, et al, Serologic evidence of Cryptococcus neoformans infection in early childhood. Pediatrics 2001; 107: E66.
8. Dromer F, Robin O, Dupont B. Isolation of Cryptococcus neoformans from Asian patient in France: evidence for dormant infection in healthy subjects. J Med Vet Mycol 1992; 30:395-7.
9. Garcia-Hermoso D, Janbon G, Dromer F. Epidemiological evidence for dormant Cryptococcus neoformans infection. J Clin Microbiol 1999; 37:3204-9.
10. Alexander BD. Cryptococcosis after solid organ transplantation. Transpl Infect Dis 2005; 7:1-3.
11. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. NIAID Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1992; 326:83-9.
12. Diamond RD, Bennett JE. Prognostic factors in cryptococcal meningitis: a study in 111 cases. Ann Intern Med 1974; 80:176-81.
13. Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001; 33:690-9.
14. Dromer F, Mathoulin S, Dupont B, Brugiére O, Letenneur L. Comparison of the efficacy of amphotericin B and fluconazole in the treatment of Cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. French Cryptococcosis Study Group. Clin Infect Dis 1996; 22(Suppl):S154-60.
15. Cruz MC, Del Poeta M, Wang P, et al. Immunosuppressive and non-immunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin. Antimicrob Agents Chemother 2000; 44:143-9.
16. Odom A, Muir S, Lim E, Toffaletti DL, Perfect J, Heitman J. Calcineurin is required for virulence of Cryptococcus neoformans. EMBO J 1997; 16:2576-89.
17. Dumont FJ, Staruch MJ, Koprak SL, et al. The immunosuppressive and toxic affects of FK-506 are mechanically related: pharmacology of a novel antagonist of FK-506 and rapamycin. J Exp Med 1992; 176:751-60.
18. Ascioglu S, Rex JH, Bennett JE, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14.
19. Singh N, Lortholary O, Alexander BD, et al. Antifungal management practices and evolution of infection in organ transplant recipients with C. neoformans infection. Transplantation 2005;80:1033-9.
20. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15.
21. Jean SS, Fang CT, Shau WY, et al. Cryptococcaemia: clinical features and prognostic factors. QJM 2002; 95:511-8.
22. Fleuridor R, Lyles RH, Pirolski L. Quantitative and qualitative differences in the serum antibody profiles of human immunodeficiency virus-infected persons with and without Cryptococcus neoformans meningitis. J Infect Dis 1999; 180:1526-35.
23. Subramaniam K, French N, Pirofski LA. Cryptococcus neoformans-reactive and total immunoglobulin profiles of HIV-infected and HIV-uninfected Ugandans. Clin Diagn Lab Immunol 2005; 12:1168-76.
24. DeShaw M, Pirofski L. Antibodies to Cryptococcus neoformans capsular polysaccharide glucoronoxylomannan are ubiquitious in the serum of HIV+ and HIV- individuals. Clin Exp Immunol 1995; 99:425-32.
25. Jalali Z, Ng N, Singh N, Pirofski L. Antibody response to Cryptococcus neoformans capsular pollysaccharide glucoronoxylomannan in patients with solid organ transplants. Clin Vaccine Immunol 2006; 13:740-6.
26. Maitta RW, Datta K, Chang Q, et al. Protective and non-protective human IgM monoclonal antibodies to Cryptococcus neoformans glucoronoxylomannan manifest different specificity and gene use. Infect Immun 2004; 72:4810-8.
27. 1. J Immunol 2003; 170:3621-30.
28. Doron S, Ruthazer R, Werner BG, Rabson A, Snydman DR. Hypogammaglobulinemia in liver transplant recipients: incidence, timing, risk factors, and outcomes. Transplantation 2006; 81:697-703.
29. Corales R, Chua J, Mawhorter S, et al. Significant post-transplant hypogammaglobulinemia in six heart transplant recipients: an emerging clinical phenomenon? Transpl Infect Dis 2000; 2:133-9.
30. Goldfarb NS, Avery RK, Goormastic M, et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation 2001; 71:242-6.
31. Gonzalez-Quintela A, Lopez-Ben S, Perez LF, Grana B, Varela M. Time-course changes of serum immunoglobulins (IgA, IgG, IgM) after liver transplantation for alcoholic cirrhosis. Transpl Immunol 2003; 11:73-7.
32. Alexander J, Limaye AP, Ko CW, Bronner MP, Kowdley KV. Association of hepatic iron overload with invasive fungal infection in liver transplant recipients. Liver Transpl 2006; 12:1799-804.
33. Boon AP, Adams DH, Buckels J, McMaster P. Cerebral aspergillosis in liver transplantation. J Clin Pathol 1990;43:114-8.
34. Torre-Cisneros J, Lopez OL, Kusne S, Martinez AJ, Starzl TE. CNS aspergillosis in organ transplantation: a clinicopathologic study. J Neurol Neurosurg Psychiatry 1993; 56:188-93.
35. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005; 18:44-9.
36. Sole A, Morant P, Salavert M, Pemán J, Morales P. Aspergillus in lung transplant recipients: risk factors and outcome. Valencia Lung Transplant Group. Clin Microbiol Infect 2005; 11:359-65.
37. Mehrad B, Paciocco G, Martinez FJ, et al. Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest 2001; 119:169-75.
38. Cardenas ME, Lim E, Heitman J. Mutations that perturb cyclophilin A ligand binding pocket confer cyclosporin A resistance in Saccharomyces cerevisiae. J Biol Chem 1995; 270:20997-1002.
39. Cruz MC, Goldstein AL, Blankenship JR, et al. Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO J 2002; 21:546-59.
40. Cruz MC, Sia RAL, Olson M, Cox CM, Heitman J. Comparisons of the roles of calcineurin in physiology and virulence in serotype D and serotype A strains of Cryptococcus neoformans. Infect Immun 2000; 68:982-5.
41. Gorlach J, Fox DS, Cutler NS, Cox GM, Perfect JR, Heitman J. Identification and characterization of a highly conserved calcineurin binding protein, CBP1/calcipressin, in Cryptococcus neoformans. EMBO J 2000; 19:1-12.
42. Perfect JR, Durack DT. Effects of cyclosporine in experimental cryptococcal meningitis. Infect Immun 1985; 50:22-6.
43. Nosanchuk JD, Shoham S, Fries BC, Shapiro DS, Levitz SM, Casadevall A. Evidence of zoonotic transmission of Cryptococcus neoformans from a pet cockatoo to an immunocompromised patient. Ann Intern Med 2000; 132:205-8.
44. Hoang LM, Maguire JA, Doyle P, Fyfe M, Roscoe DL. Cryptococcus neoformans infections in Vancouver Hospital and Health Sciences Centre (1997-2002): epidemiology, microbiology and histopathology. J Med Microbiol 2004; 53:935-40.
45. Del Poeta M, Cruz MC, Cardenas ME, Perfect J, Heitman J. Synergistic antifungal activities of bafilomycin A, fluconazole and the pneumocandin MD-0991 caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob Agents Chemother 2000; 44:739-46.
46. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931-40.
47. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3:178-85.
48. Morris PJ, Russell NK. Alemtuzumab (Campath-1H): a systematic review in organ transplantation. Transplantation 2006;81:1361-7.
49. Fung J, Kelly D, Kadry Z, Patel-Tom K, Eghtsad B. Immunosuppression in liver transplantation: beyond calcineurin inhibitors. Liver Transpl 2005;11:267-80.